Pharmacodynamics, Pharmacovigilance & Pharmacogenetics Flashcards

1
Q

Why are protein binding interactions important?

A

Important for:

  • IV drugs
  • Short half lives (rapidly cleared)
  • Narrow therapeutic index
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the CYP450 inducers?

PCBRAS

A
P - Phenytoin 
C - Carbamazepine
B - Barbituates
R - Rifampicin
A - Alcohol (chronic use)
S - Sulphonylureas & St. John's wort
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the CYP450 inhibitors?

ODEVICES

A
O - Omeprazole 
D - Disulfiram
E - Erythromycin
V - Valproate
I - Isoniazid
C - Cimetidine & Ciprofloxacin
E - Ethanol (acutely)
S - Sulphonamides
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is pharmacovigilance?

A

The process of identifying & then responding to safety issues about marketed drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are Type A ADRs?

A
Predictable
Dose dependent
Exaggerated pharmacological response
Common - 80% ADRs
High morbidity, low mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What are Type B ADRs?

A
Unpredictable
Independent of dose
Not expected from known pharmacology
Rare - 20% ADRs
High mortality
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe pre-marketing clinical studies (vs routine clinical experience

A
Relatively small no. of patients
Type of patients restricted
Limited duration of treatment
Specialist doctors
High level of patient monitoring
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe routine clinical experience (vs pre-marketing clinical studies

A
Large no. of patients
Patients - guided by indication
Duration of treatment - guided by indication
Usually any doctor
Low level of patient monitoring
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What limitations of pre-marketing clinical studies are there in identifying drug safety issues?

A
Relatively small no. of patients treated
Frequent exclusion of pts who may be at risk of greater ADRs
Structured nature of clinical trials
 - limited duration of treatment
 - restricted dodses
 - experienced specialist investigations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

How can we identify ADRs?

A

Spontaneous reporting
Cohort studies
Case control studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are the advantages & disadvantages of spontaneous reporting?

A
Good at generating new ADR signals (hypotheses)
Doesn't usually confirm hypotheses
Can characterise the ADR
May identify risk factors
Cannot calculate incidence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Why does under reporting of ADRs occur?

A

F - Failure of pts to report ADR to their doctor
A - ADR is too trivial (e.g. minor rash)
I - Ignorance of reporting (and its procedures)
L - Lack of time
U - Uncertainty of relationship of drug to presentation
R - Relating to duration of marketed drug
E - Experience & familiarity with the ADR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is pharmacogenetics?

A

The science of understanding how different individual genotypes relate to different drugs & thus know which drugs are safe & effective for each individual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is pharmacogenomics?

A

Pharmacogenetics applied to the entire genome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What potential risk factors are there for drug inefficacy or toxicity?

A
Drug-drug interactions
Age
Renal & liver function
Concurrent illness
Lifestyle variables - smoking/alcohol
Genetic variation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe the relationship between genetics and RAAS

A

Young caucasians - higher RAAS activity - ACEi/ARB treatment will lower BP more effectively
Older & Afro-caribbean - lower RAAS activity - 1st line CCBs/Thiazides

17
Q

What are the 4 main pharmacokinetic factors? (ADME)

A

Absorption
Distribution
Metabolism
Excretion

18
Q

What are the 4 main pharmacodynamic factors?

A

Receptors
Ion channels
Transporters
Enzymes